📊 ALZN Key Takeaways
Is Alzamend Neuro, Inc. (ALZN) a Good Investment?
Alzamend Neuro is a pre-revenue pharmaceutical company in a critical financial deterioration phase, with revenue collapsing 87.7% YoY to just $1.7K while operating losses remain severe at $5.9M. The company is burning cash rapidly at $5.3M annually with minimal liquidity cushion, making near-term solvency a material concern despite holding $2.7M in cash reserves.
Alzamend Neuro remains fundamentally very weak, with essentially no commercial revenue, deeply negative operating profitability, and continued cash burn that is large relative to its balance sheet. While losses improved year over year and leverage is low, the company’s liquidity is tight and its financial profile still depends heavily on external funding rather than durable operating performance.
Why Buy Alzamend Neuro, Inc. Stock? ALZN Key Strengths
- Maintains positive stockholders equity of $2.2M providing minimal balance sheet foundation
- Cash on hand of $2.7M covers approximately 5 months of current burn rate
- Low debt burden (0.00x debt-to-equity) eliminates refinancing risk
- Debt appears minimal, with no meaningful long-term debt burden on the balance sheet
- Cash and equivalents of $2.71M provide some near-term operating flexibility
- Net loss and diluted EPS improved year over year, indicating modest reduction in loss intensity
ALZN Stock Risks: Alzamend Neuro, Inc. Investment Risks
- Revenue near zero at $1.7K indicates complete absence of commercial traction or product sales
- Current ratio of 0.97x indicates immediate liquidity stress with liabilities nearly exceeding current assets
- Operating cash burn of $5.3M annually will exhaust cash reserves within months without capital injection, creating existential solvency risk
- Extreme negative margins across all profitability metrics indicate unsustainable operating model
- Pre-revenue stage with no clear path to profitability or positive cash flow
- Revenue is negligible and fell 87.7% year over year, signaling extremely weak business scale and poor growth quality
- Operating and free cash flow are deeply negative, creating ongoing financing risk
- Liquidity is strained with a 0.97x current ratio and losses that materially exceed equity
Key Metrics to Watch
- Monthly cash burn rate and runway to insolvency
- Revenue generation and clinical trial progression
- Upcoming capital raises and dilution risk
- Operating expense reduction initiatives
- Cash burn relative to cash balance and any improvement in operating cash flow
- Revenue traction and whether the company can materially reduce net losses without repeated capital raises
Alzamend Neuro, Inc. (ALZN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
ALZN Profit Margin, ROE & Profitability Analysis
ALZN vs Healthcare Sector: How Alzamend Neuro, Inc. Compares
How Alzamend Neuro, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Alzamend Neuro, Inc. Stock Overvalued? ALZN Valuation Analysis 2026
Based on fundamental analysis, Alzamend Neuro, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Alzamend Neuro, Inc. Balance Sheet: ALZN Debt, Cash & Liquidity
ALZN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Alzamend Neuro, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-132.33 indicates the company is currently unprofitable.
ALZN Revenue Growth, EPS Growth & YoY Performance
Alzamend Neuro, Inc. Dividends, Buybacks & Capital Allocation
ALZN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Alzamend Neuro, Inc. (CIK: 0001677077)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ALZN
What is the AI rating for ALZN?
Alzamend Neuro, Inc. (ALZN) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ALZN's key strengths?
Claude: Maintains positive stockholders equity of $2.2M providing minimal balance sheet foundation. Cash on hand of $2.7M covers approximately 5 months of current burn rate. ChatGPT: Debt appears minimal, with no meaningful long-term debt burden on the balance sheet. Cash and equivalents of $2.71M provide some near-term operating flexibility.
What are the risks of investing in ALZN?
Claude: Revenue near zero at $1.7K indicates complete absence of commercial traction or product sales. Current ratio of 0.97x indicates immediate liquidity stress with liabilities nearly exceeding current assets. ChatGPT: Revenue is negligible and fell 87.7% year over year, signaling extremely weak business scale and poor growth quality. Operating and free cash flow are deeply negative, creating ongoing financing risk.
What is ALZN's revenue and growth?
Alzamend Neuro, Inc. reported revenue of $1.7K.
Does ALZN pay dividends?
Alzamend Neuro, Inc. does not currently pay dividends.
Where can I find ALZN SEC filings?
Official SEC filings for Alzamend Neuro, Inc. (CIK: 0001677077) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ALZN's EPS?
Alzamend Neuro, Inc. has a diluted EPS of $-1.89.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ALZN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Alzamend Neuro, Inc. has a STRONG SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ALZN stock overvalued or undervalued?
Valuation metrics for ALZN: ROE of -270.2% (sector avg: 15%), net margin of -345,980.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ALZN stock in 2026?
Our dual AI analysis gives Alzamend Neuro, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ALZN's free cash flow?
Alzamend Neuro, Inc.'s operating cash flow is $-5.3M, with capital expenditures of N/A. FCF margin is -308,940.2%.
How does ALZN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -345,980.8% (avg: 12%), ROE -270.2% (avg: 15%), current ratio 0.97 (avg: 2).